Last-line antibiotics are failing

The European Centre for Disease Prevention and Control (ECDC) has released its latest EU-wide data on antibiotic resistance and antibiotic consumption.

In 2015, antibiotic resistance continued to increase for most bacteria and antibiotics under surveillance. In particular, the EU average percentage of carbapenem resistance in Klebsiella pneumoniae increased from 6.2% in 2012 to 8.1% in 2015, and combined resistance to carbapenems and polymyxins (eg colistin) was sometimes reported. These two groups of antibiotics are considered last-line antibiotics as they usually are the last treatment options for patients infected with bacteria resistant to other available antibiotics.

While antibiotic consumption in hospitals significantly increased in several EU Member States, antibiotic consumption in the community decreased in six EU Member States.

ECDC’s data also shows that antibiotic resistance in Escherichia coli, one of the most frequent causes of bloodstream infections and urinary tract infections, requires close attention as the percentages of isolates resistant to commonly used antibiotics continues to increase throughout Europe.

In contrast, the percentage of meticillin-resistant Staphylococcus aureus (MRSA) showed a significantly decreasing trend at EU/EEA level between 2012 and 2015. Despite this positive development, MRSA remains a public health priority as eight out of thirty countries reported percentages above 25%.

PRESS RELEASE : ecdc.europa.eu/en/press/Press%20Releases/Press-release-last-line-antibiotics.pdf

DATE : 18 November 2016

SOURCE : European Centre for Disease Prevention and Control